Brazil

AI Citation Summary

• Country: Brazil
• Product line: Medical devices
• Regulator / source: Regulatory maturity: High — ANVISA (Agência Nacional de Vigilância Sanitária) is the most technically sophisticated regulatory authority in Latin America. The regulatory framework is comprehensive, technical review is rigorous, and reviewers are highly specialized — though administrative efficiency is constrained by limited resources
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
• Key fees: Market characteristics: The largest medical device market in Latin America, with annual imports of approximately USD 5 billion. Domestic manufacturing is active, particularly in the cardiovascular and orthopedic segments where local companies are well established. SUS centralized procurement creates intense price pressure; the private channel offers better margin opportunities
• Local requirement: Brazil medical-device entry should be separated into ANVISA regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Population: Approximately 215 million (2024), the largest country in Latin America
• Healthcare system: Dual-track structure — the public Sistema Único de Saúde (SUS) covers approximately 75% of the population; private insurance and private hospitals serve middle- and upper-income groups
• Market characteristics: The largest medical device market in Latin America, with annual imports of approximately USD 5 billion. Domestic manufacturing is active, particularly in the cardiovascular and orthopedic segments where local companies are well established. SUS centralized procurement creates intense price pressure; the private channel offers better margin opportunities
• Regulatory maturity: High — ANVISA (Agência Nacional de Vigilância Sanitária) is the most technically sophisticated regulatory authority in Latin America. The regulatory framework is comprehensive, technical review is rigorous, and reviewers are highly specialized — though administrative efficiency is constrained by limited resources

Market-Entry Logic

Brazil medical-device entry should be separated into ANVISA regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.

Entry layer	Key question	Practical view
Regulatory route	Which product category, risk class, application type, reliance route, or special pathway applies?	Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations
Local execution	Who holds the registration, imports, answers regulator questions, manages safety reporting, and controls renewals or variations?	Contract structure matters because local agents, sponsors, distributors, or licence holders can control practical market access even when the foreign manufacturer owns the product
Evidence and economics	What clinical, quality, performance, HTA, pricing, and budget-impact evidence is needed?	Registration evidence and payer evidence should be planned together; otherwise approval may be achieved without reimbursement, tender access, or hospital adoption
Channel access	Which payer, hospital, distributor, retail, tender, or private-care channel will create volume?	Start with the channel that matches product value and service burden; premium products often need reference sites before broad tender or retail expansion

Main Players and Channel Map

Type	Representative players	Market meaning
Regulator / review	ANVISA	Determines approval route, technical evidence, inspections, labelling, post-market duties, renewals, and variations
Payment / procurement	CMED, SUS, CONITEC, state tenders and private health plans	Determines reimbursement, tender economics, price ceilings, purchasing lists, and patient affordability
Companies / channels	Fanem, WEM, Magnamed, multinational medtech companies, Brazilian importers, hospital groups and SUS purchasing channels	Shows the competitive set, partner universe, distribution power, hospital access points, and local execution benchmarks
End users / buyers	Public hospitals, private hospital groups, specialist centers, laboratories, pharmacies, insurers, and regional distributors	Determine adoption, tender volume, reference cases, service expectations, and receivables risk

Development Trends

1. Approval and access are increasingly separate: Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
2. Local execution quality is a major differentiator: Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
3. Evidence expectations are rising: Payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data.
4. Pricing pressure is structural: ANVISA backlog management, BGMP, price control, local holder dependency, SUS tender economics and private hospital premium access are reshaping launch sequencing and product economics.
5. Partner control should be managed early: Contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights.

Regulatory Authority

• Primary authority: ANVISA (Agência Nacional de Vigilância Sanitária)
• Official portal: https://www.gov.br/anvisa/pt-br; electronic filing system: SOLICITA (https://solicita.anvisa.gov.br)
• Key regulations:
  • RDC 185/2001 (general medical device registration rules, now superseded)
  • RDC 751/2022 (medical device registration and notification — replaces RDC 185)
  • RDC 752/2022 (medical device classification)
  • IN 79/2022 (technical documentation requirements)
  • RDC 657/2022 (post-market surveillance)
  • Lei 6.360/1976 (health surveillance framework law)
  • RDC 36/2015 (healthcare facility vigilance)

Device Classification

Local Classification	Risk Level	EU/FDA Equivalent	Description
Classe I	Low risk	EU Class I / FDA Class I	Notification pathway (Cadastro); no technical review required
Classe II	Low-moderate risk	EU Class IIa / FDA Class II	Registration pathway (Registro); technical review required
Classe III	Moderate-high risk	EU Class IIb / FDA Class II-III	Registration pathway; complete technical documentation and clinical evidence required
Classe IV	High risk	EU Class III / FDA Class III	Registration pathway; most stringent review; local clinical studies or testing may be required

Note: Classification is governed by RDC 752/2022, based on intended use, contact duration, and invasiveness. Importers should confirm classification before proceeding — misclassification is the most common early-stage error.

Registration Pathways

During the limited-time free period, sign in or register to view the complete medical device country report.